Vytorin and Zetia add depression to labels
Executive Summary
Depression is being added to the list of adverse reactions reported with ezetimibe use in labels for Merck/Schering Plough's Vytorin (ezetimibe/simvastatin) and Schering's Zetia (ezetimibe). Following a "changes being effected supplement" submitted by the sponsors, the Adverse Reactions section now includes information related to postmarketing experience with ezetimibe. The cholesterol-lowering drugs have been under significant political and market pressure following disclosure of results from the ENHANCE trial, showing that Vytorin failed to reduce arterial plaque better than simvastatin alone (1"The Pink Sheet," Jan. 28, 2008, p. 21)
You may also be interested in...
FDA To Review Vytorin Data: ENHANCEd Label To Follow?
FDA expects to complete a review of data from the ENHANCE study for Merck and Schering-Plough's Vytorin within nine months, Office of New Drugs Director John Jenkins announced Jan. 25
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.